Summary of the National Advisory Committee on Immunization (NACI) rapid response: Updated guidance on the use of Imvamune® for the prevention of mpox
Canada Communicable Disease Report · 29.04.2026 · 52 (4) · 116-122
DOI: 10.14745/ccdr.v52i04a02 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canada Communicable Disease Report, online erschienen am 29.04.2026. Verfasst von Joshua Montroy und 3 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Immunization Surveillance and Programs, Public Health Agency of Canada, Ottawa, ON. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Centre for Immunization Surveillance and Programs, Public Health Agency of Canada, Ottawa, ON.
- Department of Pediatrics, McGill University, Montréal, QC.
- Department of Medicine, University of Alberta, Edmonton, AB.
Zitieren
APA
Montroy, J., Salvadori, M., Forbes, N., & Klein, K. (2026). Summary of the National Advisory Committee on Immunization (NACI) rapid response: Updated guidance on the use of Imvamune® for the prevention of mpox. Canada Communicable Disease Report, 52(4), 116-122. https://doi.org/10.14745/ccdr.v52i04a02
Vancouver
Montroy J, Salvadori M, Forbes N, Klein K. Summary of the National Advisory Committee on Immunization (NACI) rapid response: Updated guidance on the use of Imvamune® for the prevention of mpox. Canada Communicable Disease Report. 2026;52(4):116-122. doi:10.14745/ccdr.v52i04a02
BibTeX
@article{Montroy2026,
author = {Montroy, Joshua and Salvadori, Marina and Forbes, Nicole and Klein, Kristin},
title = {Summary of the National Advisory Committee on Immunization (NACI) rapid response: Updated guidance on the use of Imvamune® for the prevention of mpox},
journal = {Canada Communicable Disease Report},
year = {2026},
volume = {52},
number = {4},
pages = {116--122},
doi = {10.14745/ccdr.v52i04a02}
}
EUVIMED